The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics

Innate and adaptive immune systems are built-in homeostatic functions of many multicellular organisms and protect the host against foreign pathogens and infections. Dysregulation of the molecular mechanisms of the immune system can result in autoimmune diseases. The immune system can also be harness...

Descripción completa

Detalles Bibliográficos
Autores: Miles, James, Ward, Stephen G., Larijani, Banafshé
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/296841
Acceso en línea:http://hdl.handle.net/10261/296841
Access Level:acceso abierto
Palabra clave:Adaptive immunity
CTLA-4/CD80
FRET/FLIM
Immune checkpoints
Immune surveillance
Innate immunity
PD-1/PD-L1
id ES_3efb93c5b7e92df5eb2bcb81a4ee425e
oai_identifier_str oai:digital.csic.es:10261/296841
network_acronym_str ES
network_name_str España
repository_id_str
spelling The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeuticsMiles, JamesWard, Stephen G.Larijani, BanafshéAdaptive immunityCTLA-4/CD80FRET/FLIMImmune checkpointsImmune surveillanceInnate immunityPD-1/PD-L1Innate and adaptive immune systems are built-in homeostatic functions of many multicellular organisms and protect the host against foreign pathogens and infections. Dysregulation of the molecular mechanisms of the immune system can result in autoimmune diseases. The immune system can also be harnessed and manipulated to provide targeted cancer therapies, some of them relying on the blockade of immune-checkpoint receptors. Two prominent immune checkpoints, PD-1/PD-L1 and CTLA-4/CD80, comprise receptor–ligand pairs that prevent the host immune cells from attacking host tissues. However, cancer cells upregulate the respective PD-L1 and CD80 ligands for PD-1 and CTLA-4 and thereby evade the host-immune response. Therapeutic drugs that block PD-1/PD-L1 and CTLA-4/CD80 interactions re-enable the immune system to attack cancer cells, but their prognostic biomarker remains challenging. In this review, we discuss how the use of quantitative molecular imaging can be exploited to predict the response to anti-PD-1/PD-L1 therapies and to identify cancer patients who would benefit from them.The work reviewed from the manuscript, Sanchez-Magraner et al. (2020), was in part funded by the Bikaintek grant for industrial doctorates in the Basque Country. The work reviewed from Miles et al. (2017) acknowledges the funding from the Spanish Ministry of Economy for the grants (grant number BFU 2011-28566) and Basque Government through the BERC 3602014–2017; the Spanish Ministry of Economy and Competitiveness (MINECO).Peer reviewedJohn Wiley & SonsFederation of European Biochemical SocietiesEusko JaurlaritzaComisión Asesora de Investigación Científica y Técnica, CAICYT (España)Ministerio de Economía y Competitividad (España)Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202320232022info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_dcae04bcPublisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/296841reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.1002/1873-3468.14480Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2968412026-05-22T06:33:51Z
dc.title.none.fl_str_mv The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics
title The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics
spellingShingle The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics
Miles, James
Adaptive immunity
CTLA-4/CD80
FRET/FLIM
Immune checkpoints
Immune surveillance
Innate immunity
PD-1/PD-L1
title_short The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics
title_full The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics
title_fullStr The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics
title_full_unstemmed The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics
title_sort The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics
dc.creator.none.fl_str_mv Miles, James
Ward, Stephen G.
Larijani, Banafshé
author Miles, James
author_facet Miles, James
Ward, Stephen G.
Larijani, Banafshé
author_role author
author2 Ward, Stephen G.
Larijani, Banafshé
author2_role author
author
dc.contributor.none.fl_str_mv Eusko Jaurlaritza
Comisión Asesora de Investigación Científica y Técnica, CAICYT (España)
Ministerio de Economía y Competitividad (España)
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Adaptive immunity
CTLA-4/CD80
FRET/FLIM
Immune checkpoints
Immune surveillance
Innate immunity
PD-1/PD-L1
topic Adaptive immunity
CTLA-4/CD80
FRET/FLIM
Immune checkpoints
Immune surveillance
Innate immunity
PD-1/PD-L1
description Innate and adaptive immune systems are built-in homeostatic functions of many multicellular organisms and protect the host against foreign pathogens and infections. Dysregulation of the molecular mechanisms of the immune system can result in autoimmune diseases. The immune system can also be harnessed and manipulated to provide targeted cancer therapies, some of them relying on the blockade of immune-checkpoint receptors. Two prominent immune checkpoints, PD-1/PD-L1 and CTLA-4/CD80, comprise receptor–ligand pairs that prevent the host immune cells from attacking host tissues. However, cancer cells upregulate the respective PD-L1 and CD80 ligands for PD-1 and CTLA-4 and thereby evade the host-immune response. Therapeutic drugs that block PD-1/PD-L1 and CTLA-4/CD80 interactions re-enable the immune system to attack cancer cells, but their prognostic biomarker remains challenging. In this review, we discuss how the use of quantitative molecular imaging can be exploited to predict the response to anti-PD-1/PD-L1 therapies and to identify cancer patients who would benefit from them.
publishDate 2022
dc.date.none.fl_str_mv 2022
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_dcae04bc
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/296841
url http://hdl.handle.net/10261/296841
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.1002/1873-3468.14480
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv John Wiley & Sons
Federation of European Biochemical Societies
publisher.none.fl_str_mv John Wiley & Sons
Federation of European Biochemical Societies
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406602745872384
score 15,81155

Similares en LA Referencia